The oncology drug development consultancy, Physiomics signed on the Servier Group, an international pharmaceutical company headquartered in France, as a new client on Friday.
Servier’s key therapy areas include cancer, with a particular emphasis on immunotherapies and monoclonal antibodies for difficult-to-treat diseases with significant unmet medical needs.
Physiomics will use its Virtual Tumour software platform to study and simulate the effect of a range of immuno-oncology combinations in development utilising Servier medicines in pre-clinical and clinical settings.
The project will be completed in the next 7-8 months, according to the forecast.
“We are delighted to have been selected by Servier, one of France’s leading pharmaceutical companies with a truly global outlook as its partner for this modelling and simulation project focused on pre-clinical and translational modelling of a novel immuno-oncology agent in development. We look forward to working with its talented scientists,” said Physiomics CEO, Dr Jim Millen.
Physiomics’ shares fell 1% to 4.5p on the announcement of its contract with the Servier Group.